A new era for castrate resistant prostate cancer: a treatment review and update

Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
Mei Ka FongAnthony Jarkowski

Abstract

The purpose of this review article is to present the current treatment options for castrate resistant prostate cancer in addition to the recently approved agents and their role in treatment. The biology of prostate cancer and the data supporting the use of traditional chemotherapeutic options in castrate resistant prostate cancer are reviewed. The newly approved agents, sipuleucel-T, cabazitaxel, and abiraterone, are presented as well. The studies that led to the approval of these three agents are discussed in this article as well as their current and potential roles in the treatment of castrate resistant prostate cancer. New mechanisms, drugs, and clinically relevant molecular targets show survival advantage and are new options available for patients after traditional chemotherapy. The roles of these new agents have yet to be further clarified in future studies.

References

Aug 17, 1989·The New England Journal of Medicine·E D CrawfordP J Goodman
Jun 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I F TannockK C Murphy
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E J Small, N J Vogelzang
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P W KantoffN J Vogelzang
Dec 22, 1999·The Journal of Urology·H W DaniellP T Stratte
Nov 22, 2001·Journal of the National Cancer Institute·K NishimuraA Okuyama
Feb 12, 2002·The Journal of Clinical Endocrinology and Metabolism·Matthew R SmithPhilip W Kantoff
Jul 31, 2003·BJU International·C F HeynsUNKNOWN South African Triptorelin Study Group
Mar 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric J SmallNicholas J Vogelzang
Jun 3, 2004·Journal of the National Cancer Institute·Fred SaadUNKNOWN Zoledronic Acid Prostate Cancer Study Group
Aug 24, 2004·Current Cancer Drug Targets·Z CuligA Hobisch
Oct 8, 2004·The New England Journal of Medicine·Ian F TannockUNKNOWN TAX 327 Investigators
Oct 8, 2004·The New England Journal of Medicine·Daniel P PetrylakE David Crawford
Jan 14, 2005·The New England Journal of Medicine·Vahakn B ShahinianJames S Goodwin
Apr 20, 2005·Journal of Cellular Biochemistry·Zoran CuligAlfred Hobisch
May 19, 2006·Cancer Research·Peter J M HendriksenGuido Jenster
May 30, 2006·Advances in Immunology·Charles G DrakeDrew M Pardoll
Jun 3, 2006·Cancer Research·Raanan BergerMassimo Loda
Jul 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric J SmallRobert M Hershberg
Sep 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nancy L KeatingMatthew R Smith
Apr 4, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D Andrew LoblawUNKNOWN American Society of Clinical Oncology
Jul 20, 2007·Journal of General Internal Medicine·Ellen F T YeeRichard M Hoffman
Jul 28, 2007·Cancer·Christopher S SaigalUNKNOWN Urologic Diseases in America Project
Oct 11, 2007·Journal of the National Cancer Institute·Henry K TsaiPeter R Carroll
May 7, 2008·Annals of Internal Medicine·Amir QaseemUNKNOWN Clinical Efficacy Assessment Subcommittee of the American College of Physicians
Jul 16, 2008·Current Opinion in Pharmacology·Timothy A YapJohann S de Bono
Sep 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-Pascal MachielsJoseph Kerger
Jan 14, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G SpitaleriO De Cobelli
Jan 17, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alain C MitaAnthony W Tolcher
Aug 13, 2009·The New England Journal of Medicine·Matthew R SmithUNKNOWN Denosumab HALT Prostate Cancer Study Group
Sep 10, 2009·The Journal of Clinical Endocrinology and Metabolism·Michael Stowasser
Feb 10, 2010·Journal of the National Comprehensive Cancer Network : JNCCN·James L Mohler
Feb 10, 2010·Journal of the National Comprehensive Cancer Network : JNCCN·Philip J Saylor, Matthew R Smith
Feb 18, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel C DanilaHoward I Scher

❮ Previous
Next ❯

Citations

Jan 23, 2016·Cellular Oncology (Dordrecht)·Sharanjot Saini
Mar 21, 2013·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Anthony JarkowskiNikhil I Khushalani
Apr 27, 2017·Oncotarget·Daniela VanacoreGaetano Facchini
Sep 3, 2016·Oncotarget·Kirandeep SekhonSharanjot Saini
Jun 28, 2013·Asian Pacific Journal of Cancer Prevention : APJCP·Sharifa Wan Puteh EzatNor Hazla Mohamed Haflah
May 29, 2021·Future Science OA·Deng KaiyuanZang Yunhui

❮ Previous
Next ❯

Methods Mentioned

BETA
chemical castration

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.